[{"id":"91129fdb-7ee9-4817-acf7-e8fc2da77a2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03338972","created_at":"2021-01-18T16:29:36.458Z","updated_at":"2025-02-25T14:37:39.553Z","phase":"Phase 1","brief_title":"Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma","source_id_and_acronym":"NCT03338972","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" SDC1","pipe":" | ","alterations":" SDC1 expression","tags":["SDC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SDC1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • FCARH143 • FHVH-BCMA-T • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 11/29/2017","start_date":" 11/29/2017","primary_txt":" Primary completion: 05/03/2021","primary_completion_date":" 05/03/2021","study_txt":" Completion: 03/22/2022","study_completion_date":" 03/22/2022","last_update_posted":"2023-09-08"},{"id":"9873163b-80bf-417d-b751-f5882bf14bd1","acronym":"CIF-PM","url":"https://clinicaltrials.gov/study/NCT03983486","created_at":"2021-01-18T19:35:31.364Z","updated_at":"2024-07-02T16:36:43.070Z","phase":"","brief_title":"Rationale for Cytogenetic Risk Stratification by Imaging Flow Cytometry in Multiple Myeloma","source_id_and_acronym":"NCT03983486 - CIF-PM","lead_sponsor":"Centre Hospitalier Universitaire, Amiens","biomarkers":" CD38 • SDC1","pipe":" | ","alterations":" SDC1 expression","tags":["CD38 • SDC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SDC1 expression"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/30/2018","start_date":" 11/30/2018","primary_txt":" Primary completion: 02/10/2020","primary_completion_date":" 02/10/2020","study_txt":" Completion: 02/10/2020","study_completion_date":" 02/10/2020","last_update_posted":"2020-07-17"},{"id":"74313848-6b6f-4543-9ddd-07a7c1b55596","acronym":"","url":"https://clinicaltrials.gov/study/NCT03185871","created_at":"2021-01-18T15:42:31.720Z","updated_at":"2024-07-02T16:36:53.683Z","phase":"Phase 2","brief_title":"Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses","source_id_and_acronym":"NCT03185871","lead_sponsor":"University of Wisconsin, Madison","biomarkers":" PGR • CD163 • SDC1 • PTGS2 • VIM • CD68","pipe":" | ","alterations":" PGR positive • PTGS2 expression • SDC1 expression","tags":["PGR • CD163 • SDC1 • PTGS2 • VIM • CD68"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive • PTGS2 expression • SDC1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e celecoxib oral"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/20/2017","start_date":" 09/20/2017","primary_txt":" Primary completion: 10/10/2018","primary_completion_date":" 10/10/2018","study_txt":" Completion: 10/10/2018","study_completion_date":" 10/10/2018","last_update_posted":"2019-11-15"},{"id":"6154975f-d9b3-4c92-af99-c367d972f2f7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03767725","created_at":"2021-01-18T18:38:32.761Z","updated_at":"2024-07-02T16:37:04.814Z","phase":"Phase 1","brief_title":"Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma","source_id_and_acronym":"NCT03767725","lead_sponsor":"Shenzhen Second People's Hospital","biomarkers":" SDC1","pipe":" | ","alterations":" SDC1 expression","tags":["SDC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SDC1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Unknown status","enrollment":" Enrollment 10","initiation":"Initiation: 06/02/2018","start_date":" 06/02/2018","primary_txt":" Primary completion: 06/01/2021","primary_completion_date":" 06/01/2021","study_txt":" Completion: 09/01/2021","study_completion_date":" 09/01/2021","last_update_posted":"2018-12-10"}]